EasySep™ Human Naïve CD8+ T Cell Isolation Kit II

总览

使用 EasySep™ 人初始 CD8⁺ T 细胞分选试剂盒 II，通过免疫磁珠负选，可轻松高效地从新鲜的人外周血单个核细胞（PBMC）样本中分离高纯度的初始 CD8⁺ T 细胞（CD8⁺CD45RA⁺CCR7⁺ 且 CD45RO⁻CD57⁻CD56⁻）。EasySep™ 技术结合单克隆抗体的特异性与无柱磁系统的简便性，已在发表的研究中广泛应用超过 20 年。

在此 EasySep™ 负选过程中，不需要的细胞通过抗体复合物和磁珠标记。表达以下标记的细胞将被去除：CD4、CD14、CD16、CD19、CD20、CD36、CD56、CD94、CD123、CD244、IgM、GlyA、TCRγδ、CD45RO 和 CD57。使用 EasySep™ 磁极进行无柱分选，磁珠标记的细胞被去除，只需将未标记的初始CD8⁺ T 细胞倒入或移取至新的管中即可。仅需 11 分钟即可完成磁珠分选过程，分离后的初始CD8⁺ T细胞可直接用于下游应用，例如流式细胞术、细胞培或DNA/RNA 提取。

本产品可替代 EasySep™ 人初始 CD8⁺ T 细胞富集试剂盒（产品号 #19258），实现更快速的细胞分离。

了解更多关于 EasySep™ 免疫磁性技术的工作原理，或了解如何使用 RoboSep™ 实现全自动化的免疫磁性细胞分离。您也可以选择使用 EasySep™ 人初始 CD8⁺ T 细胞分选试剂盒 II 制备的即用型、符合伦理的冻存人外周血 CD8⁺CD45RA⁺ T 细胞。探索更多优化实验流程的产品，包括培养基、补充物、抗体等。

磁极兼容性
• EasySep™磁极（产品号 #18000）
• “The Big Easy” EasySep™磁极（产品号 #18001）
• EasyEights™ EasySep™磁极（产品号 #18103）
• RoboSep™-S（产品号 #21000）

分类
细胞分选试剂盒

细胞类型
T 细胞，T 细胞，CD8+

种属
人

样本来源
PBMC

分选方法
负选

应用
细胞分选

品牌
EasySep，RoboSep

研究领域
免疫

查看更多显示更少

实验数据

Figure 1. Typical EasySep™ Human Naive CD8 T Cell Isolation Profile

Starting with fresh PBMCs, the naïve CD8+ T cell content (CD8+CD45RA+CCR7+ and CD45RO-CD57-CD56-) of the isolated fraction is typically 93.7 ± 2.4% (mean ± SD), using the purple EasySep™ Magnet. In the above example, the purities of the start and final isolated fractions are 6.8% and 94.2%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968RF

Lot #

All

Language

English

Document Type

Product Information Sheet

Product Name

EasySep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

RoboSep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human Naïve CD8+ T Cell Isolation Kit II

Catalog #

17968

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for T Cell Research

Cell Sourcing

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Workflow Stages for T Cell Engineering

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Cell Cryopreservation

相关材料与文献

Induction of memory-like CD8+ T cells and CD4+ T cells from human naive T cells in culture. Y. Tokumoto et al. Clinical and experimental immunology 2022 jan

Abstract

Memory T cells are crucial players in vertebrate adaptive immunity but their development is incompletely understood. Here, we describe a method to produce human memory-like T cells from naive human T cells in culture. Using commercially available human T-cell differentiation kits, both purified naive CD8+ T cells and purified naive CD4+ T cells were activated via T-cell receptor signaling and appropriate cytokines for several days in culture. All the T-cell activators were then removed from the medium and the cultures were continued in hypoxic condition (1% O2 atmosphere) for several more days; during this period, most of the cells died, but some survived in a quiescent state for a month. The survivors had small round cell bodies, expressed differentiation markers characteristic of memory T cells and restarted proliferation when the T-cell activators were added back. We could also induce memory-like T cells from naive human T cells without hypoxia, if we froze the activated T cells or prepared the naive T cells from chilled filter buffy coats.

View publication

Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. A. O. Cohen et al. Oncoimmunology 2022

Abstract

Cancer immunotherapy approaches target signaling pathways that are highly synonymous between CD4 and CD8 T-cell subsets and, therefore, often stimulate nonspecific lymphocyte activation, resulting in cytotoxicity to otherwise healthy tissue. The goal of our study was to identify intrinsic modulators of basic T lymphocyte activation pathways that could discriminately bolster CD8 anti-tumor effector responses. Using a Tbc1d10c null mouse, we observed marked resistance to a range of tumor types conferred by Tbc1d10c deficiency. Moreover, tumor-bearing Tbc1d10c null mice receiving PD-1 or CTLA-4 monotherapy exhibited a 33% or 90% cure rate, respectively. While Tbc1d10c was not expressed in solid tumor cells, Tbc1d10c disruption selectively augmented CD8 T-cell activation and cytotoxic effector responses and adoptive transfer of CD8 T cells alone was sufficient to recapitulate Tbc1d10c null tumor resistance. Mechanistically, Tbc1d10c suppressed CD8 T-cell activation and anti-tumor function by intersecting canonical NF-$\kappa$B pathway activation via regulation of Map3k3-mediated IKK$\beta$ phosphorylation. Strikingly, none of these cellular or molecular perturbations in the NF-$\kappa$B pathway were featured in Tbc1d10c null CD4 T cells. Our findings identify a Tbc1d10c-Map3k3-NF-$\kappa$B signaling axis as a viable therapeutic target to promote CD8 T-cell anti-tumor immunity while circumventing CD4 T cell-associated cytotoxicity and NF-$\kappa$B activation in tumor cells.

View publication

Efficient derivation of chimeric-antigen receptor-modified TSCM cells. E. Kranz et al. Frontiers in immunology 2022

Abstract

Chimeric-antigen receptor (CAR) T-cell immunotherapy employs autologous-T cells modified with an antigen-specific CAR. Current CAR-T manufacturing processes tend to yield products dominated by effector T cells and relatively small proportions of long-lived memory T cells. Those few cells are a so-called stem cell memory T (TSCM) subset, which express na{\{i}}ve T-cell markers and are capable of self-renewal and oligopotent differentiation into effector phenotypes. Increasing the proportion of this subset may lead to more effective therapies by improving CAR-T persistence; however there is currently no standardized protocol for the effective generation of CAR-TSCM cells. Here we present a simplified protocol enabling efficient derivation of gene-modified TSCM cells: Stimulation of na{\"{i}}ve CD8+ T cells with only soluble anti-CD3 antibody and culture with IL-7 and IL-15 was sufficient for derivation of CD8+ T cells harboring TSCM phenotypes and oligopotent capabilities. These in-vitro expanded TSCM cells were engineered with CARs targeting the HIV-1 envelope protein as well as the CD19 molecule and demonstrated effector activity both in vitro and in a xenograft mouse model. This simple protocol for the derivation of CAR-TSCM cells may facilitate improved adoptive immunotherapy."

View publication

View All Publications

物种	人类
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源	PBMC
Selection Method	Negative

EasySep™人Naïve CD8+ T细胞分选试剂盒 II

产品号 #17968

产品号 #17968RF

产品号 #（选择产品）

产品号 #17968_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

EasySep™人Naïve CD8+ T细胞分选试剂盒 II

产品号 #17968

产品号 #17968RF

产品号 #（选择产品）

产品号 #17968_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (9)

文献 (3)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台